
==== Front
Case Rep Nephrol
Case Rep Nephrol
CRIN
Case Reports in Nephrology
2090-6641
2090-665X
Wiley

10.1155/2024/5556426
Case Series
Unusual Cases of Monoclonal Gammopathy of Renal Significance
https://orcid.org/0000-0002-2399-7654
Chen Anjellica 1
https://orcid.org/0000-0002-5985-6466
Turcotte Anna-Ève anna-eve.turcotte@usherbrooke.ca
2
https://orcid.org/0000-0002-4264-0300
Higgins Sarah 2
https://orcid.org/0000-0002-7057-7492
Pavic Michel 3
https://orcid.org/0000-0003-4472-8207
Ethier Vincent 3
https://orcid.org/0009-0006-1738-5981
Lévesque Dion Vincent 4
1 Department of Internal Medicine Université de Sherbrooke, Sherbrooke, Canada
2 Department of Nephrology Centre Hospitalier Universitaire de Sherbrooke Université de Sherbrooke, Sherbrooke, Canada
3 Department of Hematology Centre Hospitalier Universitaire de Sherbrooke Université de Sherbrooke, Sherbrooke, Canada
4 Department of Pathology CIUSSS de la Mauricie-et-du-Centre-du-Québec, Trois-Rivières, Canada
Academic Editor: Yoshihide Fujigaki

2024
12 9 2024
2024 555642617 2 2024
6 6 2024
24 6 2024
Copyright © 2024 Anjellica Chen et al.
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Monoclonal gammopathy of renal significance (MGRS) is a rare entity describing patients with renal impairment related to the secretion of immunoglobulins without hematological criteria for treatment of a specific disease. We present 3 cases of MGRS identified at our center that were either rare or difficult to diagnose. Case Presentations. The first patient presented with monoclonal membranoproliferative glomerulonephritis in the context of known chronic lymphocytic leukemia (CLL), diagnosed about 10 years prior. She presented with nephritic syndrome with serum protein electrophoresis revealing an IgG/lambda peak of less than 1 g/L, stable from the last few years. A renal biopsy confirmed a diagnosis of monoclonal membranoproliferative glomerulonephritis with granular IgG and C3 deposits of various sizes. The second patient presented with renal TMA in the context of IgM MGUS. The patient was admitted for acute nephritic syndrome and thrombotic microangiopathy. Serum protein electrophoresis demonstrated IgM/kappa paraprotein at 1.8 g/L, with a kappa/lambda ratio of 5.48. Renal biopsy demonstrated endocapillary proliferative glomerulonephritis associated with the presence of numerous monotypic IgM/kappa intracapillary pseudothrombi. Characteristic changes of thrombotic microangiopathy were also described. The third patient presented with immunotactoid glomerulonephritis likely from small B-cell lymphoma that later transformed to DLBCL. The patient presented with acute renal failure with IgM/kappa paraprotein of less than 1 g/L on electrophoresis and with a kappa/lambda ratio of 7.09. A diagnosis of immunotactoid glomerulonephritis was made on renal biopsy. Bone marrow with limited specimen revealed a B-cell infiltrate. Biopsy of a breast lesion was compatible with diffuse large B-cell lymphoma (DLBCL). Lymphomatous cells expressed IgM/kappa, thus confirming paraprotein-associated renal lesion.

Conclusion

We described 3 different cases of MGRS, highlighting the diversity of renal pathohistological presentations and different associated lymphoproliferative disorders. Biopsy should rapidly be considered, as early diagnosis of MGRS is essential to initiate clone-directed therapy promptly to prevent progression to ESRD or hematologic progression to malignancy.
==== Body
pmc1. Introduction

Renal impairment caused by the secretion of monoclonal immunoglobulins by clonal B-cells or plasma cells, whether premalignant or nonmalignant, has been recognized. Monoclonal gammopathy of unknown significance (MGUS) is defined by less than 30 g/L of paraprotein or monoclonal immunoglobulin secreted by the plasma cell, less than 10% of bone marrow plasma cell population, and the lack of end-organ damage [1–6]. The term monoclonal gammopathy of clinical significance (MGCS) is used to designate patients who would, in other respect, have MGUS but also have organ damage directly related to the immunoglobulin secretion. Some of these disorders, such as AL amyloidosis, impact many organs including the kidneys [7].

In 2012, the International Kidney and Monoclonal Gammopathy Research Group suggested the term monoclonal gammopathy of renal significance (MGRS) [8] to describe a subset of patients with renal impairment related to the secretion of immunoglobulins without hematological criteria for treatment of a specific disease [5, 9, 10]. In 2017, the definition of MGRS was updated to also include B-cell lymphoproliferative disorders and plasma cell dyscrasias not meeting the criteria for hematologic treatment as causes of MGRS. Thus, this new definition includes certain chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, indolent Waldenström macroglobulinemia, and smouldering multiple myeloma [10]. Thus, under the right clinical context, patients with renal impairment and abnormal serum protein electrophoresis should raise the suspicion for MGRS.

Diagnosis of MGRS requires kidney biopsy. Immunofluorescence on biopsy may reveal the presence of monoclonal immunoglobulin deposits within the renal parenchyma [2, 8, 11]. After performing light chain quantification and protein electrophoresis, immunofixation must be done to distinguish between monoclonal immunoglobulin band and other unusual distributions [4–6, 11]. If polyclonal hypergammaglobulinemia is found, a different approach is mandated to elucidate the cause of kidney injury [12]. On the other hand, if a monoclonal band is present, identifying the paraprotein secreting clone must be done with bone marrow aspiration and biopsy. When no clone is identified or when IgM secretion is detected, CT scan or PET scan must be done to identify a suspicious plasmacytoma or adenopathy [2, 5, 8].

We may classify MGRS according to its histopathology (Figure 1). Renal lesions can be classified into organized or nonorganized immunoglobulin deposits, or nonimmunoglobulin lesions [14, 15]. We present 3 cases of MGRS identified at our center that were either rare or difficult to diagnose.

2. Case Presentations

2.1. Case 1

The first patient was a woman in her 80s, evaluated in nephrology for nephritic syndrome. The patient was known for CLL for about 10 years, without treatment requirement (Rai stage 0). A gradual increase in creatinine was noted, reaching 211 μmol/L (DFG 18.3 mL/min/1.73 m2) when consulted by a nephrologist (Table 1). Urinalysis revealed the presence of albuminuria, as well as 21 to 50 red blood cells per field and a few leucocytes. The protein/creatinine ratio was 0.99 g/g. The patient then presented with new-onset hypertension. Serum protein electrophoresis revealed an IgG/lambda peak of less than 1 g/L, stable over the last few years. Kappa and lambda light chains were measured at 30.3 mg/L and 103.3 mg/L, respectively, giving a ratio of 0.29, which was considered low for patients with kidney impairment. Bone marrow biopsy demonstrated monoclonal lymphocytosis with lambda+ and CD10+ phenotype. Antibody testing, complement levels, and infectious workup were all negative.

A renal biopsy was done (Figure 2), confirming a diagnosis of monoclonal membranoproliferative glomerulonephritis. Immunofluorescence was notable for the presence of mesangial and subendothelial lambda light chains as well as granular IgG and C3 deposits of various sizes. Congo red staining was negative, and bone marrow biopsy was unremarkable. The patient received 6 cycles of rituximab and chlorambucil (former standard treatment for CLL) for the treatment of MGRS, with creatinine improvement and stabilisation around 100–140. The serum protein electrophoresis remained stable after treatment with an IgG/lambda peak of less than 1 g/L.

2.2. Case 2

The second patient was a woman in her 80s who was admitted for rapidly progressive acute renal failure in the context of nephritic syndrome and thrombotic microangiopathy. The creatinine level was at 184 μmol/L (DFG 21.3 ml/min/1.73 m2) at admission (Table 1) from a baseline of 50 μmol/L and increased to 287 μmol/L (DFG 21.3 ml/min/1.73 m2) the following day. With the bicarbonate level at 10 mmol/L and potassium at 5.1 mmol/L in an oliguric patient, hemodialysis was started immediately. Serum protein electrophoresis demonstrated IgM/kappa paraprotein at 1.8 g/L. Serum kappa and lambda light chains were measured at 79 mg/L and 14 mg/L, respectively, with a ratio of 5.48. PET scan was negative, and bone marrow biopsy showed no evidence of malignancy. Thus, the patient was diagnosed with IgM MGUS.

The protein/creatinine ratio (PCR) was at 2.27 g/g, while the albumin/creatinine ratio (ACR) was at 2.4 mg/mmol. The discordant results between the PCR and ACR were explained by the presence of urine light chains. Urinalysis showed variable count of red blood cells. Finally, thrombocytopenia and hemolytic anemia with schistocytes were noted on blood smear. ADAMTS13 activity was calculated at 22%, thus eliminating thrombotic thrombocytopenic purpura. Serum cryoglobulins measured at three different intervals all came back negative.

Renal biopsy demonstrated endocapillary proliferative glomerulonephritis associated with the presence of numerous monotypic IgM/kappa intracapillary pseudothrombi (Figure 3). Characteristic changes of thrombotic microangiopathy were also described, with multiple fibrinous intracapillary thrombi. Congo red staining was negative. These findings were compatible with a diagnosis of monoclonal intracapillary deposits and thrombotic microangiopathy related to MGRS in the context of IgM MGUS.

Empiric steroid therapy was started before biopsy results, given the severity of initial presentation with a need for hemodialysis. The patient received Solu-Medrol 1 g daily for 3  days, followed by prednisone 60 mg daily. After obtaining biopsy results, plasmapheresis was initiated and hemodialysis was subsequently rapidly discontinued. Treatment with plasmapheresis was continued for 4  months, after which a deterioration of the renal function was noted. Rituximab was thus started at 375 mg/m2 for 4 doses. Two months later, the patient was completely weaned off from prednisone. A follow-up is done a few months later, creatinine was stable at around 110, and there was no evidence of proteinuria. Furthermore, hemolytic parameters were normal and there was no thrombocytopenia. However, the serum protein electrophoresis continued to demonstrate an IgM/kappa paraprotein at 1.1 g/L. The serum kappa light chains remained elevated at 156 mg/L.

2.3. Case 3

The third patient was a woman in her 60s who was admitted for progressive renal failure, with an increase in the creatinine level from 66 μmol/L (DFG 72.6 ml/min/1.73 m2) to 117 μmol/L (DFG 42 ml/min/1.73m2) a year later (Table 1). Urinalysis revealed the presence of 51 to 100 red blood cells per field, with a protein/creatinine ratio of 1.28 g/g. IgM/kappa paraprotein was also noted to be less than 1 g/L on electrophoresis. Serum light chains kappa and lambda were at 77 mg/L and 10 mg/L, respectively, with an elevated ratio of 7.09.

Suspecting paraprotein-related renal dysfunction, bone marrow biopsy was attempted, but the tissue sample was insufficient for the analysis. The patient was started on empiric treatment with prednisone 60 mg daily.

Renal biopsy was done; however, the specimen quality was limited. Thus, immunofluorescence was impossible to perform, but Congo red staining was negative. With little information from the biopsy, autoimmune glomerulonephritis was erroneously diagnosed. Treatment with CellCept was started, which was changed to Myfortic before completely halting treatment about two years later as the renal function was stable.

Two months later, the creatinine level rapidly rose from 130–150 μmol/L (DFG 30 to 40 ml/min/1.73 m2) to 180 μmol/L (DFG 24.6 ml/min/1.73 m2). Myfortic was restarted. However, the creatinine level continued to rise to 323 μmol/L (DFG 12.1 ml/min/1.73 m2) a few months later. Renal biopsy was repeated. This time, a focally proliferative glomerulonephritis was described. Important tubulointerstitial lesions with fibrosis and atrophy, as well as granular glomerular and tubular IgG, IgM, C3, C1Q, and kappa deposits, were noted. Glomeruli were not permeable for electron microscopy. However, revision of electron microscopy from the first biopsy showed the presence of granular deposits resembling microtubules along the epithelial surface of the glomerular basement membrane. The diagnosis of immunotactoid glomerulonephritis was made. Bone marrow biopsy was repeated. A B-cell infiltrate and monotypic IgM/kappa plasma cells were suspected, without being able to establish a clear diagnosis due to poor quality of the specimen. Thus, conservative management was decided.

Around the same time as the kidney function started to deteriorate, a breast lesion was noted. Biopsy of the breast mass was compatible with diffuse large B-cell lymphoma (DLBCL). Lymphomatous cells expressed IgM/kappa, thus confirming paraprotein-associated renal lesion. The patient received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 6 cycles; however, the kidney function did not recover and dialysis was initiated. The IgM/kappa paraprotein remained stable on electrophoresis. Serum light chains kappa remained elevated.

3. Discussion

We described 3 different cases of MGRS, highlighting the diversity of renal pathohistological presentations and different associated lymphoproliferative disorders. The first patient presented with monoclonal membranoproliferative glomerulonephritis in the context of CLL. The second patient had TMA renal lesions from IgM MGUS, which is a very rare MGRS presentation. Finally, the third patient presented with immunotactoid glomerulonephritis likely from small B-cell lymphoma that later transformed to DLBCL.

Despite renal impairment from secreted paraprotein, none of these patients had criteria for treatment of their hematological disease. Indeed, in the first case, the patient's CLL did not warrant treatment with a Rai staging of 0 [16], yet it was likely the cause of the patient's glomerulonephritis, although it is not excluded that the patient could also have a second hematological disease, such as MGUS, that could be the cause of the paraprotein-related renal lesions. Published reports of renal impairment in the context of CLL often highlight the association between the renal dysfunction and paraprotein secreted by B-cell clones [17, 18], with monoclonal membranoproliferative glomerulonephritis being the most common renal presentation [18–21].

The second patient presented with renal TMA lesions in the context of IgM monoclonal gammopathy. Although monoclonal intracapillary deposits and renal TMA are well described with Waldenström macroglobulinemia [22–30], they are however less described with IgM secreting MGUS. A recent retrospective study documented an important prevalence of MGUS in patients with thrombotic microangiopathy, suggesting monoclonal immunoglobulin as a triggering factor [29]. Others have reported associations between these two entities, with the latest consensus from the International Kidney and Monoclonal Gammopathy Research Group adding thrombotic microangiopathy as a provisional status to its classification of lesions associated with MGRS [13]. TMA is not associated with direct paraprotein deposition in the renal parenchyma but rather presents with disordered complement regulation caused indirectly by paraprotein [31]. TMA may be kidney-limited, which highlights the importance of doing a kidney biopsy. Secondary causes of TMA, including pregnancy, infection, drug, autoimmune, transplant, and malignancy, should be evaluated. Genetic analysis for mutations in the complement alternative pathway should be obtained [31], although this was not done in our patient as genetic analyses were not easily accessible.

Finally, the third patient presented with immunotactoid glomerulonephritis, which is a rare cause of MGRS [13, 32]. It is interesting to note that the diagnosis of DLBCL was made a few months after the diagnosis of immunotactoid glomerulonephritis. It is thus most likely that the patient first developed a small lymphocytic lymphoma, which triggered a renal impairment (MGRS), before transforming to DLBCL. Indeed, the presence of the monoclonal IgM/kappa gammopathy on initial electrophoresis, later findings of a B-cell infiltrate with monoclonal IgM/kappa (without classification) on bone marrow biopsy, and finally the diagnosis of DLBCL with similar IgM/kappa expression, all support this hypothesis which triggered a renal impairment (MGRS) before transforming to DLBCL. Associations between immunotactoid glomerulonephritis and CLL or indolent lymphoproliferative processes are well described [33, 34], whereas only one case report of immunotactoid glomerulonephritis in the context of DLBCL was found [35].

As MGRS was only first described in 2012, the true incidence is unknown. In patients with MGUS who underwent renal biopsy, 38% had MGRS lesions in a Chinese retrospective study [36] and 40% had MGRS lesions in a Mayo Clinic retrospective study from 2013 to 2018 [37]. The diagnosis is often delayed because of the requirement of biopsy for diagnosis. Strong predictors of having MGRS include the presence of an elevated free light chain ratio [36], proteinuria, and hematuria [37]. Thus, patients presenting with these features should rapidly be assessed and considered for kidney biopsy to establish a rapid diagnosis to avoid treatment delay and poorer outcomes. Furthermore, patients with MGUS and either atypical evolution of chronic kidney disease, aged less than 50  years, and eligible for kidney transplant should also be further evaluated for potential kidney transplant. However, there is a high risk of recurrence after kidney transplantation [38–41] if the monoclonal gammopathy is not eliminated. This highlights the importance of treating the underlying hematological disease.

Therefore, although paraprotein secreting B-clone may not meet hematological criteria for treatment, when kidney damage from paraprotein results in MGRS, treatment of the underlying clone is warranted to prevent the progression to end-stage renal disease (ESRD) [14, 15, 31, 42]. Multiple case reports have shown renal improvement with treatment of the underlying clone [43, 44]. Furthermore, as observed with the third patient, patients with MGRS are at higher risk of progressing to the corresponding hematological malignancy [14, 45, 46], which also supports the need for treatment.

Although clone-directed therapy is warranted, there is currently no clear guidelines for treatment of MGRS. Therapy is often based on current chemotherapy regimens used for the treatment of the associated malignant clones, as there are very few studies specifically on treatment of MGRS clones, with most reports based on nonrandomized data.

Thus, many patients with IgG, IgA, and light chain plasma cell dyscrasia (non-IgM) are treated with bortezomib [15, 47–49] as a single agent or in combination with other drugs. Studies on proteasome inhibitors are however all retrospective, with no randomized controlled trial specifically for treatment of MGRS. However, in multiple myeloma, bortezomib-containing regimens have shown to reduce tumor load and improve the kidney function [50–52].

The first patient in our case series with CLL was treated with rituximab and chlorambucil. In a retrospective study from 1975 to 2014 at the Mayo Clinic [21], all five patients with CLL complicated by MGRS treated with rituximab, cyclophosphamide, and steroid (RCP-based) regimen had recovery of the renal function, as opposed to none of the three patients with rituximab with or without steroids. However, since then, treatment for CLL has shifted to tyrosine kinase inhibitors, with now case reports of patients receiving ibrutinib in combination of rituximab-based regimens for treatment of MGRS [53]. It is however still unclear what the optimal treatment for paraprotein-associated renal lesions in CLL is.

The second patient had renal TMA in the context of IgM MGUS. As this is a rare hematological entity with a rare renal presentation, there is little evidence for treatment of MGRS-related IgM paraprotein. Rituximab-based therapy, as received by our patient, can be considered [42] as it is usually the treatment of choice for the associated malignancy of Waldenström macroglobulinemia.

Finally, a B-cell clone could only be identified in the third patient after progression from an indolent lymphoproliferative process to DLBCL. Thus, the patient received R-CHOP. However, ideally, the patient should have been treated for MGRS before progression to DLBCL, although the optimal treatment regimen would have been unclear as there are no specific treatment guidelines for MGRS clone-directed therapy.

Optimal timing for starting chemotherapy is also unknown in patients with MGRS. Treatment is also challenged by the lack of MGRS response criteria. Studies [47, 48, 54] are based either on multiple myeloma response criteria [55], or immunoglobulin light chain amyloidosis treatment response criteria [56], as amyloidosis is a common MGRS presentation [36, 37]. However, there is no renal response criterion for either of these consensuses, as it was not designed with MGRS in mind. Thus, development of MGRS-specific response criteria is called for, as treatment is warranted mostly for prevention of progression to ESRD.

Rapid management and multidisciplinary approach are essential [15]. In previous series, kidney biopsies were deferred in approximately 40% of cases because of lack of awareness of kidney disease by the hematologist, or lack of awareness of MGUS by the nephrologist [37]. It is therefore important to increase physician awareness of MGRS and to encourage physicians to search for the association between renal disease and monoclonal gammopathy. Finally, our work highlights the importance of the nephrologist's and hematologist's cooperation for early diagnosis and optimal care management.

4. Conclusion

We present 3 singular cases of MGRS from our institution. These cases highlight the diversity of renal histopathological presentation and associated hematological disorder. Biopsy should rapidly be considered in patients with renal impairment and any B-cell lymphoproliferative disorders or plasma cell dyscrasia not meeting hematological criteria for treatment. Early diagnosis of MGRS is essential to initiate clone-directed therapy promptly to prevent progression to ESRD or hematologic progression to malignancy. Finally, we hope for a greater recognition of MGRS and for the elaboration of eventual randomized studies for treatment.

Data Availability

Due to patient confidentiality issues, data will not be available.

Consent

No written consent has been obtained from the patients as there are no patient identifiable data included in this case report/series.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Figure 1 Classification of MGRS. Adapted from Leung et al. [13].

Figure 2 Case 1: pathology slides. (a) Immunofluorescence (IF) microscopy demonstrates C3 granular mesangial and subendothelial deposits of high intensity. (b) IF demonstrates IgG deposits with the same pattern as C3 deposits. (c) Light microscopy shows the PAS membranoproliferative pattern of injury. Nodular mesangial expansion, endocapillary proliferation, subendothelial deposits, and glomerular basement membrane double contour are noted. (d) IF fixation of kappa light chain was negative. (e) IF demonstrates lambda deposits with the same pattern as C3 deposits. (f) Light microscopy Masson's trichrome stain shows the membranoproliferative pattern of injury.

Figure 3 Case 2: pathology slides. (a) Light microscopy shows numerous PAS-positive hyaline pseudothrombi (arrows) as well as a fibrin thrombus (star) (PAS 400x). (b) PAS-positive hyaline pseudothrombi filling the glomerular capillary lumen (PAS 600x). (c) Fibrin thrombosis at the glomerular vascular pole (Jones 200x). (d) Immunofluorescence microscopy demonstrates intracapillary and mesangial staining for kappa light chain. Intracapillary fixation was also noted for IgM, C3, and C1q but not for the lambda light chain. (e) Immunofluorescence microscopy shows fixation of fibrinogen in the glomerular vascular pole, compatible with the thrombosis. (f) Electron microscopy shows unorganized immune-type deposits of intracapillary and subendothelial localisation. Intracapillary fibrin deposits were also noted.

Table 1 Patient laboratory results at presentation.

 	Patient 1	Patient 2	Patient 3	
Serum creatinine (μmol/L)	211	184	117	
DFG (mL/min/1.73 m2)	18.3	21.3	42	
Urine albumin/creatinine ratio (0–1.9 mg/mmol)	—	2.4	 	
Urine protein/creatinine ratio (0–0.2 g/g)	0.99	2.27	1.28	
Serum protein electrophoresis	IgG/lambda peak <1 g/L	IgM/kappa 1.8 g/L	IgM/kappa <1 g/L	
Serum-free light chains (mg/L)	Kappa 30.3	Kappa 79	Kappa 77	
Kappa (3.3–19.4 mg/L)	Lambda 103.3	Lambda 14	Lambda 10	
Lambda (5.7–26.3 mg/L)	Ratio 0.29	Ratio 5.48	Ratio 7.09	
Bence Jones	Lambda	Kappa	Kappa	
Urine protein electrophoresis	Nonselective glomerular proteinuria	Tubular proteinuria	 	
	
Total serum calcium	
C3 (0.90–1.80 g/L)	N	0.43	N	
C4 (0.10–0.45 g/L)	N	0.08	<0.05	
Antineutrophil cytoplasmic antibody (ANCA)	Negative	Negative	—	
Antiglomerular basement membrane antibody (anti-GBM)	Negative	Negative	—	
Antinuclear factor	Negative	—	Negative	
Rheumatoid factor	Negative	Negative	Negative	
Hepatitis B and C serologies	Negative	Negative	Negative	
Serum cryoglobulins	Negative	—	Negative	
Red Congo staining on biopsy	Negative	Negative	Negative	
C-reactive protein (0–8 mg/L)	5.3	39.1	100	
IgG (7–16 g/L)	5.48	5.10	1.6	
IgM (0.7–4 g/L)	0.29	16.4	7.02	
IgA (0.4–2.30 g/L)	0.70	0.68	0.17
==== Refs
1 Sethi S. Rajkumar S. V. D’Agati V. D. The complexity and heterogeneity of monoclonal immunoglobulin–associated renal diseases Journal of the American Society of Nephrology 2018 29 7 1810 1823 10.1681/asn.2017121319 2-s2.0-85049389233 29703839
2 Leung N. Bridoux F. Hutchison C. A. Monoclonal gammopathy of renal significance: When MGUS is no longer undetermined or insignificant Blood 2012 120 22 4292 4295 10.1182/blood-2012-07-445304 2-s2.0-84869779556 23047823
3 Glavey S. V. Leung N. Monoclonal gammopathy: The good, the bad and the ugly Blood Reviews 2016 30 3 223 231 10.1016/j.blre.2015.12.001 2-s2.0-84951831904 26732417
4 van de Donk N. W. Palumbo A. Johnsen H. E. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: Recommendations from the European Myeloma Network Haematologica 2014 99 6 984 996 10.3324/haematol.2013.100552 2-s2.0-84901710991 24658815
5 Parry H. M. Pratt G. Hutchison C. A. Monoclonal gammopathy of undetermined significance: An update for nephrologists Advances in Chronic Kidney Disease 2012 19 5 291 296 10.1053/j.ackd.2012.07.006 2-s2.0-84865412217 22920639
6 Go R. S. Rajkumar S. V. How I manage monoclonal gammopathy of undetermined significance Blood 2018 131 2 163 173 10.1182/blood-2017-09-807560 2-s2.0-85040454259 29183887
7 Marinkovic A. Zypchen L. N. Chan J. Chen L. Y. Parkin S. Monoclonal gammopathy of clinical significance: What the rheumatologist needs to know The Lancet Rheumatology 2022 4 5 e362 e373 10.1016/S2665-9913(21)00348-9 38294033
8 Bridoux F. Leung N. Hutchison C. A. Diagnosis of monoclonal gammopathy of renal significance Kidney International 2015 87 4 698 711 10.1038/ki.2014.408 2-s2.0-84926520891 25607108
9 Rosner M. H. Edeani A. Yanagita M. Glezerman I. G. Leung N. Paraprotein–related kidney disease: Diagnosing and treating monoclonal gammopathy of renal significance Clinical Journal of the American Society of Nephrology 2016 11 12 2280 2287 10.2215/cjn.02920316 2-s2.0-85021701644 27526705
10 Hogan J. J. Weiss B. M. Bridging the divide: An onco-nephrologic approach to the monoclonal gammopathies of renal significance Clinical Journal of the American Society of Nephrology 2016 11 9 1681 1691 10.2215/cjn.03160316 2-s2.0-85011803298 27416775
11 Correia S. O. Santos S. Malheiro J. Cabrita A. Martins L. S. Santos J. Monoclonal gammopathy of renal significance: Diagnostic workup World Journal of Nephrology 2017 6 2 p. 72 10.5527/wjn.v6.i2.72
12 Zhao E. J. Cheng C. V. Mattman A. Chen L. Y. C. Polyclonal hypergammaglobulinaemia: Assessment, clinical interpretation, and management The Lancet Haematology 2021 8 5 e365 e375 10.1016/S2352-3026(21)00056-9 33894171
13 Leung N. Bridoux F. Batuman V. The evaluation of monoclonal gammopathy of renal significance: A consensus report of the international kidney and monoclonal gammopathy research group Nature Reviews Nephrology 2019 15 1 45 59 10.1038/s41581-018-0077-4 2-s2.0-85058013288 30510265
14 Leung N. Bridoux F. Nasr S. H. Monoclonal gammopathy of renal significance New England Journal of Medicine 2021 384 20 1931 1941 10.1056/NEJMra1810907 34010532
15 Karam S. Haidous M. Dalle I. A. Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment Critical Reviews in Oncology 2023 183 103926 10.1016/j.critrevonc.2023.103926
16 Hallek M. Cheson B. D. Catovsky D. IWCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL Blood 2018 131 25 2745 2760 10.1182/blood-2017-09-806398 2-s2.0-85049186980 29540348
17 Leung N. Drosou M. E. Nasr S. H. Dysproteinemias and glomerular disease Clinical Journal of the American Society of Nephrology 2018 13 1 128 139 10.2215/cjn.00560117 2-s2.0-85040236535 29114004
18 Wanchoo R. Bernabe Ramirez C. Barrientos J. Jhaveri K. D. Renal involvement in chronic lymphocytic leukemia Clinical Kidney Journal 2018 11 5 670 680 10.1093/ckj/sfy026 2-s2.0-85058037547 30288263
19 Poitou-Verkinder A. L. Francois A. Drieux F. The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma: A 25-year multicenter experience PLoS One 2015 10 3 10.1371/journal.pone.0119156 2-s2.0-84926014297 e0119156
20 Vial R. Daniel L. Devos M. Chronic lymphoid leukemia and renal compliation: Report on 10 cases from Marseille over 16 years La Revue de Medecine Interne 2018 39 8 612 617 10.1016/j.revmed.2018.05.006 2-s2.0-85048187567 29891261
21 Strati P. Nasr S. H. Leung N. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience Haematologica 2015 100 9 1180 1188 10.3324/haematol.2015.128793 2-s2.0-84940916065 26088927
22 Tan S. Y. S. Sibley R. K. Belani S. Thrombotic microangiopathy with intraglomerular IgM pseudothrombi in Waldenström macroglobulinemia and IgM monoclonal gammopathy Journal of Nephrology 2018 31 6 907 918 10.1007/s40620-018-0544-9 2-s2.0-85055481861 30334170
23 Higgins L. Nasr S. H. Said S. M. Kidney involvement of patients with waldenström macroglobulinemia and other IgM-producing B cell lymphoproliferative disorders Clinical Journal of the American Society of Nephrology 2018 13 7 1037 1046 10.2215/cjn.13041117 2-s2.0-85049781129 29848505
24 Audard V. Georges B. Vanhille P. Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum Clinical Journal of the American Society of Nephrology 2008 3 5 1339 1349 10.2215/cjn.01600408 2-s2.0-53749103613 18632851
25 Morel-Maroger L. Basch A. Danon F. Verroust P. Richet G. Pathology of the kidney in waldenström’s macroglobulinemia New England Journal of Medicine 1970 283 3 123 129 10.1056/nejm197007162830304 2-s2.0-0014951812 4987279
26 Harada Y. Ido N. Okada T. Nephrotic syndrome caused by protein thrombi in glomerulocapillary lumen in Waldenström’s macroglobulinaemia: Short Report British Journal of Haematology 2000 110 4 880 883 10.1046/j.1365-2141.2000.02259.x 2-s2.0-0033760244 11054074
27 Ramos R. Poveda R. Sarra J. Domingo A. Carreras L. Grinyo J. M. Renal involvement in non-malignant IgM gammopathy Nephrology Dialysis Transplantation 2006 22 2 627 630 10.1093/ndt/gfl709 2-s2.0-33846677778
28 Vos J. M. Gustine J. Rennke H. G. Renal disease related to Waldenström macroglobulinaemia: Incidence, pathology and clinical outcomes British Journal of Haematology 2016 175 4 623 630 10.1111/bjh.14279 2-s2.0-84979518970 27468978
29 Ravindran A. Go R. S. Fervenza F. C. Sethi S. Thrombotic microangiopathy associated with monoclonal gammopathy Kidney International 2017 91 3 691 698 10.1016/j.kint.2016.09.045 2-s2.0-85008154318 27998645
30 Koga T. Yamasaki S. Nakamura H. Renal thrombotic microangiopathies/thrombotic thrombocytopenic purpura in a patient with primary Sjögren’s syndrome complicated with IgM monoclonal gammopathy of undetermined significance Rheumatology International 2013 33 1 227 230 10.1007/s00296-010-1569-0 2-s2.0-84872326201 20652270
31 Filippone E. J. Newman E. D. Li L. Gulati R. Farber J. L. Thrombotic microangiopathy, an unusual form of monoclonal gammopathy of renal significance: Report of 3 cases and literature review Frontiers in Immunology 2021 12 10.3389/fimmu.2021.780107 780107
32 Javaugue V. Bouteau I. Sirac C. Classification and therapeutic management of monoclonal gammopathies of renal significance La Revue de Medecine Interne 2018 39 3 161 170 10.1016/j.revmed.2017.03.012 2-s2.0-85018167233 28457684
33 Bridoux F. Hugue V. Coldefy O. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features Kidney International 2002 62 5 1764 1775 10.1046/j.1523-1755.2002.00628.x 2-s2.0-0036405058 12371978
34 Nasr S. H. Fidler M. E. Cornell L. D. Immunotactoid glomerulopathy: Clinicopathologic and proteomic study Nephrology Dialysis Transplantation 2012 27 11 4137 4146 10.1093/ndt/gfs348 2-s2.0-84869426735
35 Khandelwal A. Trinkaus M. A. Ghaffar H. Jothy S. Goldstein M. B. A case report of unusually long lag time between immunotactoid glomerulopathy (itg) diagnosis and diffuse large B-cell lymphoma (DLBCL) development BMC Nephrology 2016 17 1 p. 140 10.1186/s12882-016-0349-9 2-s2.0-84989871420
36 Yong Z. H. Yu X. J. Liu J. X. Zhou F. D. Wang S. X. Zhao M. H. Kidney histopathologic spectrum and clinical indicators associated with MGRS Clinical Journal of the American Society of Nephrology 2022 17 4 527 534 10.2215/cjn.12890921 35210280
37 Klomjit N. Leung N. Fervenza F. Sethi S. Zand L. Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy Journal of the American Society of Nephrology 2020 31 10 2400 2411 10.1681/asn.2020010054 32747354
38 Nasr S. H. Sethi S. Cornell L. D. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft Clinical Journal of the American Society of Nephrology 2011 6 1 122 132 10.2215/CJN.05750710 2-s2.0-79251514326 20876681
39 Leung N. Lager D. J. Gertz M. A. Wilson K. Kanakiriya S. Fervenza F. C. Long-term outcome of renal transplantation in light-chain deposition disease American Journal of Kidney Diseases 2004 43 1 147 153 10.1053/j.ajkd.2003.09.020 2-s2.0-0347359329 14712438
40 Said S. M. Cosio F. G. Valeri A. M. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft Kidney International 2018 94 1 159 169 10.1016/j.kint.2018.01.028 2-s2.0-85046141609 29716794
41 Czarnecki P. G. Lager D. J. Leung N. Dispenzieri A. Cosio F. G. Fervenza F. C. Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits Kidney International 2009 75 4 420 427 10.1038/ki.2008.577 2-s2.0-59149084228 19037251
42 Amaador K. Peeters H. Minnema M. C. Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options The Netherlands Journal of Medicine 2019 77 7 243 254 31582582
43 Hesius E. Bunthof K. Steenbergen E. de Kort E. Klein I. Wetzels J. Monoclonal gammopathy of renal significance presenting with cryoglobulinaemia type I associated severe thrombotic microangiopathy Clinical Kidney Journal 2022 15 7 1425 1428 10.1093/ckj/sfac078 35756736
44 Cheungpasitporn W. Leung N. Sethi S. Gertz M. A. Fervenza F. C. Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy Clinical Nephrology 2015 83 (2015) 06 363 369 10.5414/cn108363 2-s2.0-84940108964 25345382
45 Steiner N. Göbel G. Suchecki P. Prokop W. Neuwirt H. Gunsilius E. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: An observational study of 2935 MGUS patients Oncotarget 2017 9 2 2344 2356 10.18632/oncotarget.23412 2-s2.0-85040005338 29416776
46 Kyle R. A. Larson D. R. Therneau T. M. Long-term follow-up of monoclonal gammopathy of undetermined significance New England Journal of Medicine 2018 378 3 241 249 10.1056/nejmoa1709974 2-s2.0-85040943597 29342381
47 Khera A. Panitsas F. Djebbari F. Long term outcomes in monoclonal gammopathy of renal significance British Journal of Haematology 2019 186 5 706 716 10.1111/bjh.15987 2-s2.0-85066464742 31141168
48 Batko K. Malyszko J. Jurczyszyn A. The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance Nephrology Dialysis Transplantation 2019 34 9 1440 1452 10.1093/ndt/gfy259 2-s2.0-85072041517
49 Pampa-Saico S. Rodriguez-Mendiola N. Valles-Carboneras A. Treatment with bortezomib in dense deposit disease associated with monoclonal gammopathy of undetermined significance British Journal of Haematology 2019 184 2 302 304 10.1111/bjh.15081 2-s2.0-85059671752 29363742
50 Breitkreutz I. Heiss C. Perne A. Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure Bone Marrow Transplantation 2014 49 11 1371 1375 10.1038/bmt.2014.165 2-s2.0-84909969098 25089594
51 Scheid C. Sonneveld P. Schmidt-Wolf I. G. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial Haematologica 2014 99 1 148 154 10.3324/haematol.2013.087585 2-s2.0-84892620823 23996482
52 Cohen C. Royer B. Javaugue V. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease Kidney International 2015 88 5 1135 1143 10.1038/ki.2015.201 2-s2.0-84947563375 26176826
53 Ma T. Wang H. Su T. Wang S. Case report: Chronic lymphocytic leukemia with recurrent complement-mediated thrombotic microangiopathy and C3 glomerulonephritis Frontiers of Medicine 2022 9 10.3389/fmed.2022.813439 813439
54 Sayed R. H. Wechalekar A. D. Gilbertson J. A. Natural history and outcome of light chain deposition disease Blood 2015 126 26 2805 2810 10.1182/blood-2015-07-658872 2-s2.0-84954516000 26392598
55 Durie B. G. Harousseau J. L. Miguel J. S. International uniform response criteria for multiple myeloma Leukemia 2006 20 9 1467 1473 10.1038/sj.leu.2404284 2-s2.0-84988241358 16855634
56 Palladini G. Dispenzieri A. Gertz M. A. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes Journal of Clinical Oncology 2012 30 36 4541 4549 10.1200/jco.2011.37.7614 2-s2.0-84871772553 23091105
